| CRVS Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the CRVS shares outstanding history going back to 3/23/2016:
Also see: CRVS Market Cap History CRVS YTD Return |
CRVS Shares Outstanding History — Corvus Pharmaceuticals Share Count Over Time
As of 8/6/2026 Corvus Pharmaceuticals has 84.12 million CRVS shares outstanding. Investors often track the CRVS shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows CRVS share count trends over time, with 44 historical shares outstanding datapoints presented, dating back to 3/23/2016.
| CRVS Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CRVS Historical Shares Outstanding: +14.62% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CRVS Stock Price Chart |
| About Corvus Pharmaceuticals Inc |
| Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. We show 44 historical shares outstanding datapoints in our coverage of CRVS's shares outstanding history. Understanding the changing numbers of CRVS shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like CRVS versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching CRVS by allowing them to research CRVS shares outstanding history as well as any other stock in our coverage universe. |
| CRVS Current Stock Quote |
Quotes delayed 20 minutes  Free CRVS Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| CRVS Share Performance |
| Shares Outstanding Peers |
| Corvus Pharmaceuticals (CRVS) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
CRY Shares Outstanding History CSBR Shares Outstanding History CSII Shares Outstanding History CSTL Shares Outstanding History CSU Shares Outstanding History CTIC Shares Outstanding History CTKB Shares Outstanding History CTLT Shares Outstanding History CTMX Shares Outstanding History CTNM Shares Outstanding History More Healthcare companies » |
CRVS Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
